How Does The Impending Launch Of Several New Biosimilars For Humira Impact Formulary Coverage and Market Access?

P&T Session Ulcerative Colitis: MMIT recently held a syndicated, simulated P&T session focused on the approvals of mirikizumab and filgotinib, and the launch of Amjevita (biosimilar Humira).